公共卫生紧急状态声明到期后的COVID-19监测——美国,2023年5月11日
美国卫生与公众服务部于2020年1月31日宣布COVID-19公共卫生紧急状态,经13次续期后将于2023年5月11日到期,相关公共卫生数据收集授权同日失效。本文说明紧急状态到期后,COVID-19相关住院水平将成为疫情趋势的主要指标,以临时死亡证明数据计算的COVID-19死亡占全部报告死亡百分比将成为监测死亡率的主要指标,急诊就诊和哨兵网络检测阳性率用于早期发现趋势变化,基因组、污水和旅行者监测继续用于变异株监测,疫苗接种覆盖、疫苗效果和安全性监测继续,并指出COVID-19相关住院和死亡可通过接种更新疫苗和及时治疗在很大程度上预防。
要点
- 2023年5月11日公共卫生紧急状态到期后,COVID-19相关住院水平成为疫情趋势主要指标。
- COVID-19死亡占全部报告死亡百分比(基于临时死亡证明数据)成为监测死亡率的主要指标。
- 急诊COVID-19诊断就诊和哨兵网络检测阳性率用于早期发现趋势变化,基因组与污水监测继续。
核心结论
- 公共卫生紧急状态到期后,COVID-19相关住院水平将作为疫情趋势的主要指标,COVID-19死亡占全部报告死亡百分比将作为监测死亡率的主要指标。
- COVID-19相关住院和死亡可通过接种更新疫苗和及时给予治疗在很大程度上预防。
研究设计与样本
- 美国卫生与公众服务部根据《公共卫生服务法》第319条于2020年1月31日宣布公共卫生紧急状态,经13次续期后于2023年5月11日到期。
- 紧急状态到期后,部分公共卫生数据收集授权同日失效,本文描述后续监测指标与策略。
主要发现
- COVID-19相关住院水平将作为疫情趋势主要指标,帮助指导社区和个人关于风险与预防行为的决策。
- 基于临时死亡证明数据的COVID-19死亡占全部报告死亡百分比,将作为监测COVID-19死亡率的主要指标。
- 急诊科COVID-19诊断就诊和来自既定哨兵网络的SARS-CoV-2检测阳性百分比,将帮助发现趋势的早期变化。
- 国家基因组监测继续用于估计SARS-CoV-2变异株比例,污水监测和基于旅行者的基因组监测也继续用于监测SARS-CoV-2变异株。
- 疾病严重程度和住院相关结局通过哨兵监测和大型医疗保健数据库监测,COVID-19疫苗接种覆盖、疫苗效果(VE)和疫苗安全性监测也将继续。
临床怎么用
- COVID-19相关住院水平可用于指导社区和个人关于风险与预防行为的决策。
- 整合COVID-19和其他呼吸道病毒监测的策略可进一步指导预防工作。
- COVID-19相关住院和死亡可通过接种更新疫苗和及时给予治疗在很大程度上预防。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On January 31, 2020, the U.S. Department of Health and Human Services (HHS) declared, under Section 319 of the Public Health Service Act, a U.S. public health emergency because of the emergence of a novel virus, SARS-CoV-2.* After 13 renewals, the public health emergency will expire on May 11, 2023. Authorizations to collect certain public health data will expire on that date as well. Monitoring the impact of COVID-19 and the effectiveness of prevention and control strategies remains a public health priority, and a number of surveillance indicators have been identified to facilitate ongoing monitoring. After expiration of the public health emergency, COVID-19-associated hospital admission levels will be the primary indicator of COVID-19 trends to help guide community and personal decisions related to risk and prevention behaviors; the percentage of COVID-19-associated deaths among all reported deaths, based on provisional death certificate data, will be the primary indicator used to monitor COVID-19 mortality. Emergency department (ED) visits with a COVID-19 diagnosis and the percentage of positive SARS-CoV-2 test results, derived from an established sentinel network, will help detect early changes in trends. National genomic surveillance will continue to be used to estimate SARS-CoV-2 variant proportions; wastewater surveillance and traveler-based genomic surveillance will also continue to be used to monitor SARS-CoV-2 variants. Disease severity and hospitalization-related outcomes are monitored via sentinel surveillance and large health care databases. Monitoring of COVID-19 vaccination coverage, vaccine effectiveness (VE), and vaccine safety will also continue. Integrated strategies for surveillance of COVID-19 and other respiratory viruses can further guide prevention efforts. COVID-19-associated hospitalizations and deaths are largely preventable through receipt of updated vaccines and timely administration of therapeutics (1-4).
引用
- Silk BJ, Scobie HM, Duck WM, et al. COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration - United States, May 11, 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37167154. doi:10.15585/mmwr.mm7219e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。